We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
GlaxoSmithKline has confirmed it will face a challenging 2019 as generics of its big-selling Advair drug finally reach the US, as it continues the transformation of its business....